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ABSTRACT 
The technical aspects of quality assurance (QA) in radiation oncology as practice in the United States will be 
reviewed and updated in the spirit of offering the experience to the radiation oncology communities in the Asia-Pacific 
region. The word “technical” is used to express the organisational components or processes and not the materials within 
the QA program. A comprehensive QA program in radiation oncology will have an official statement declaring the 
quality plan for effective patient care services it provides in a document. The QA program will include all aspects of 
patient care: physical, clinical, and medical aspects of the services. The document will describe the organisational 
structure, responsibilities, checks and procedures, and resources allocated to ensure the successful implementation of the 
quality of patient management. Regulatory guidelines and guidelines from accreditation agencies should be incorporated 
in the QA program to ensure compliance. The organisational structure will have a multidisciplinary QA committee that 
has the authority to evaluate continuously the effectiveness of the QA program to provide prompt corrective 
recommendations and to request feedback as needed to monitor the response. The continuous monitoring aspects require 
meetings to be held at regular intervals with the minutes of the meetings officially recorded and documented. To ensure 
that a QA program is effective, the program itself should be audited for quality at regular intervals at least annually. It 
has been recognised that the current QA program has not kept abreast with the rapid implementation of new and 
advanced radiation therapy technologies with the most recent in image-based radiation therapy technology. The societal 
bodies (ASTRO and AAPM) and federal agency (NCI) acknowledge this inadequacy and have held workshops to 
address this issue. The challenges for the societal bodies and federal agency are numerous that include (a) the 
prescriptive methodology used may not be appropriate for currently implemented new technologies, (b) resources are 
becoming scarce, (c) advanced radiation therapy technologies have been introduced too rapidly, (d) advances in 
radiation therapy technologies have become too sophisticated and specialised with each therapy modality having its own 
separate set of equipment, for example its own dose planning software, computer system and dose delivery systems 
requiring individualised QA procedures. At the present time, industrial engineers are being recruited to assist in devising 
a methodology that is broad-based and more process-oriented risk-based formulation of QA in radiation oncology. 
© 2008 Biomedical Imaging and Intervention Journal. All rights reserved. 
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The rapid deployment of technologically advanced 
equipment to manage cancer patients has placed stress on 
the health care systems in the Asia-Pacific region. The 
incidence of cancers in the Asia-Pacific region has 
increased significantly over the past several years. This 
has been attributed to the enormous economic successes 
with impressive double-digits growth rate per year in the 
East and Southeast Asia countries and China during the 
1980s and 1990s. Such economic successes have led to 
improved standard of living with better health care 
systems resulting in fewer deaths from infectious and 
malnutrition diseases. For example, in the Seventh 
National Health Development Plan (1992-1996), the 
Thailand government had increased the health care 
budget by 54% in five years [1]. As a result, the people 
in the Asia-Pacific region live longer expanding its 
population in a much more rapid rate compared to the 
population in Europe and the USA. Aside from the rapid 
increase in the general population, the proportion of 
people who are 65 years old and older has increased at an 
even more alarming rate. For example, the population of 
China has increased by 31% over the last 25 years while 
the people over 65 years old by 81%. By comparison, the 
population in UK has risen by 6% only and the people 
older than 65 years by 7% in accordance to the Lancet 
Asia Medical Forum highlights of the “Asia and Cancer 
Management in the 21
st Century” held in April 21-27, 
2007 in Singapore [2]. These disparities are of concerns 
to the federal agencies of the respective countries in the 
Asia-Pacific since cancer affects primarily people of 
older age. If the projection is correct, the number of 
cancer cases in Asia is set to increase from 3.5 million in 
2002 to 8.1 million by 2020 if the current management 
strategies are not changed [2]. With the change to cancer 
as a high priority agenda over the previously 
malnutrition diseases, the federal agencies in their 
respective countries have to set up new infrastructures to 
deal with this new disease. Since cancers are the disease 
of the west, it is natural to import the “know-how” from 
them to expedite the handling of this disease. This means 
the importation of technologically advanced equipment, 
protocols on the training in the proper operation and 
maintenance of the equipment, and federal guidelines for 
the safe use of the equipment. This paper has been 
written with the spirit of offering the experience of the 
USA on the technical aspects of quality assurance (QA) 
program in radiation oncology to the radiation oncology 
communities in the Asia-Pacific region. It will be a 
review as well as an update engaging in the definition of 
QA, its organisational structures, the principles 
underlying QA, and lastly the current state of QA in 
keeping abreast with the rapid implementation of new 
image-based radiation therapy technologies. It is the 
hope of the authors that the presentations will show with 
sufficient clarity the inter-relationships between the 
regulatory agencies, the societies of the radiation 
oncology communities, the hospitals, the radiation 
oncologists, and its associated staff working 
synergistically to provide quality of care for patients 
undergoing radiation therapy. 
HISTORICAL REVIEW 
Quality assurance program is well-established and 
has been integrated into modern radiation oncology 
practice. This successful integration is attributed, in part 
to the principal requirement of radiation therapy where 
the maximum dose delivered is generally limited by 
normal tissue tolerances and that a large clinical response 
results from a small change in dose for some tumors. 
Hence, it is therefore critical that radiation dose must be 
delivered accurately and consistently. The publication of 
the International Commission on Radiation Units and 
Measurements (ICRU) Report No. 24 in 1976 
acknowledged that therapeutic systems should be 
capable of delivering a dose to a volume to within 5% of 
the prescribed dose [3]. The delivery of radiation therapy 
in an accurate and consistent manner is by no means 
simple because of the use of advanced technologically 
and sophisticated equipment with sets of defined 
tolerances, the involvement of multi-disciplinary 
personnel, and the meticulous tasks in the treatment 
processes. The publication of the American Association 
of Medical Physicists in Medicine (AAPM) Report No. 
13 in 1984 indicated that the possible source of treatment 
errors include tumor localisation, lack of patient 
immobilisation, field placement, human errors in 
calibration, daily patient setup, and equipment-related 
problems [4]. The subsequent publication in 1994 by 
AAPM, the Report No. 46 which supersedes AAPM 
Report No. 13, commonly referred to as the “TG-40 
report” presented a comprehensive quality assurance 
program for radiation oncology practice [5]. While the 
AAPM Report No. 13 was limited to physical aspects of 
QA, this later report has expanded into the clinical 
aspects of patient care addressing those areas which link 
together the work of the radiation oncologists, radiation 
therapists, medical dosimetrists (dose planners), and 
radiation oncology physicists. 
The introduction of image-based technologies into 
radiation oncology practice through three-dimensional 
(3D) treatment planning systems has transformed the 
radiation therapy paradigms [6]. Today, conformal 
radiation therapy (CRT) and intensity-modulated 
radiation therapy (IMRT) are the standard radiation 
therapy treatment techniques. These therapy treatment 
techniques make use of CT-Simulator scanners to 
acquire patient data making conventional simulators 
obsolete. Because of the large amount of electronic data 
acquired, patient data are now downloaded into the 
treatment planning systems through the electronic data 
transfer networks. Current treatment planning systems 
are much more sophisticated in particular having the 
ability to perform virtual treatment planning and also 
leaf-sequencing to instruct the dose delivery systems to 
properly deliver the prescribed dose sequentially. Hence 
the dose delivery systems with multileaf-collimation 
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capabilities, in some extent, have been automated. In 
addition, CRT and IMRT require a higher degree of 
precision and accuracy compared to the traditional 
treatment techniques. These requirements have led to the 
introduction of image-guided radiation therapy (IGRT) 
technology for patient setup and monitoring [7-10]. The 
ability to monitor patient motion during treatment has 
lead to the implementation of motion-gated techniques. 
The radiation oncology community has come to realize 
that their practice has evolved into a very sophisticated 
technologically driven radiation therapy practice in a 
relatively short time. This realisation questions whether 
the QA program has kept abreast with the advancement 
of radiation oncology practices [11-12].  
QUALITY ASSURANCE DEFINITION 
The term, QA defined by the International Standard 
Organization (ISO) as “all those planned or systematic 
actions necessary to provide adequate confidence that a 
product or service will satisfy given requirements for 
quality” has been adopted by AAPM TG-40 [5]. In this 
regard, and as explained in the task group report, the 
word “quality” refers to the totality of features and 
characteristics of radiation therapy services that bear on 
its ability to satisfy the stated or implied goal of effective 
patient care. The task group elaborated that the QA 
involves making sure that quality is what it should be. 
This includes a continuing evaluation of adequacy and 
effectiveness of quality to ensure prompt implementation 
of corrective measures and request feedback where 
necessary. Hence QA can be interpreted simply as a 
program consisting of systematic checks on various 
aspects of services to ensure that the declared standards 
of patient care are maintained. The World Health 
Organization (WHO) defined QA as all those procedures 
that ensure consistency of the medical prescription 
regarding the dose to the target volume, together with 
minimal dose to normal tissues, minimum exposure to 
personnel, and adequate patient monitoring to determine 
the end result of treatment [13]. 
COMPREHENSIVE QA PROGRAM 
A comprehensive QA program is a quality system 
built on a quality plan. The quality plan is the official 
statement that declares the specific quality practices, 
resources available, and activities related to patient care 
services it provides. The comprehensive QA program has 
a document that describes the organisational structure, 
responsibilities, checks and procedures, and resources 
allocated to ensure successful implementation of the 
quality of patient management. This document covers the 
quality of all aspects of patient care in the radiation 
therapy processes including (a) personnel qualification, 
(b) equipment performance, (c) fabrication process, (d) 
utilisation process, (e) render patient services, and (f) 
documentation of all aspects of radiation therapy 
delivery services. In the document, the QA checks, 
frequency of checks, action criteria, records of checks, 
and personnel responsible for performing these checks 
must be clearly defined. The QA program must be 
sufficiently comprehensive that the cumulative effects of 
uncertainties associated with complete radiation therapy 
processes can be determined. This allows tolerance 
levels and thereafter action criteria to be set for 
parameters that are being checked. The QA program 
should have a mechanism of feedback to the QA 
committee so that any shortcomings can be addressed 
and resolved promptly. Professional organisations such 
as the AAPM, American College of Medical Physics 
(ACMP), and American College of Radiology (ACR) 
have suggested guidelines in designing the QA program. 
The organisational structure should have a Quality 
Assurance Committee (QAC). The QAC members 
should consist of radiation oncologist, medical physicist, 
radiation therapist, nurse, administrator, and personnel as 
warranted, representing the multidisciplinary nature of 
the radiation oncology practice. The QAC is charged 
with authority by the Director of Radiation Oncology 
and the administration to oversee the QA program. The 
responsibility of the QAC is to set action levels and 
delegate QA checks to staff members. For example, the 
commissioning, proper clinical use, and proper 
maintenance of all radiation oncology equipment are the 
responsibilities of a radiation oncologist physicist. The 
parameter check must be specific such as each member 
knows his/her responsibilities and be trained to perform 
checks with the knowledge of what action should be 
taken if the test or action gives a result outside the 
tolerance level. Records documenting the frequency and 
results of every parameter check must be kept in an 
auditable form for review. The QAC should carefully 
review instances wherein actions are exceeded, errors are 
made, and/or procedures are discovered to be faulty, and 
so on. After the review, the QAC should formulate their 
recommendations in writing and should retain for audit 
the minutes of the meeting, the action recommended and 
the results attained. 
A quality audit needs to be performed at regular 
intervals to assess the need for improvement of the QA 
program if any. The Joint Commission on Accreditation 
of Healthcare Organization (JCAHO) requires at least an 
annual appraisal of the radiation oncology QA program. 
Although a person within the organisation can perform 
the quality audit, an outside group should also perform 
the quality audit as well. In both cases, a person not 
directly responsible for the areas being audit should 
perform the quality audit preferably in cooperation with 
the responsible personnel. Three examples are cited to 
illustrate the quality audit. The first example is the 
recommendation of ACR quality assurance program for a 
monthly audit by a designated reviewer over a sample of 
patient charts. The second example is the external review 
of programs, policies, and procedures by ACR. A 
certificate of compliance will be issued to those facilities 
that satisfy ACR criteria. Lastly, mailed 
thermoluminescent dosimeters (TLD) to an external 
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service can be used to verify the treatment unit 
calibration is consistent with the national standard. 
A successful QA program must have dedicated 
personnel, instruments for measurements, and scheduled 
time on radiotherapy equipment to perform QA tests. 
Additional manpower must be allocated to perform QA 
checks such as daily machine output or audit patient 
treatment charts. Manpower is also needed to manage the 
QA program in particular administrative work and 
coordinating with external organisations in reference to 
external auditing. QA instruments such as electrometer 
and ion chamber system are needed to check the 
performance of the radiotherapy equipment. The 
availability of time on radiotherapy equipment is of 
paramount importance because the performance of the 
equipment is what will be checked. The availability 
means that time on the treatment machines, simulators, 
CT-simulators, and treatment planning computer systems 
must be reserved during normal working hours for QA 
checks. Such QA checks may include daily constancy 
measurements performed by the radiation therapist prior 
to initiating daily treatment, monthly spot check, and 
annual full calibration on treatment units performed by 
radiation oncology physicist. There should be continuing 
education programs to familiarize the QA team members 
about organisational structure, regulatory guidelines, and 
updates as adopted in the QA program. 
REGULATORY COMPLIANCE 
There are a number of regulations that affect 
radiation oncology practice. These include the 
regulations set forth by (a) the state over the operation of 
radiation producing equipment for medical use, (b) 
Nuclear Regulatory Commission or agreement state over 
the medical use of byproduct materials, (c) 
Environmental Protection Agency (EPA) over the release 
of materials, (d) Department of Transportation (DOT) 
over the transport of radioactive materials, (e) Food and 
Drug Administration (FDA) over the use of radio-
pharmaceutical in humans, and (f) FDA and Center for 
Devices and Radiological Health (CDRH) over the use 
of medical devices. Any non-compliance to these 
regulatory guidelines can result in a penalty and an 
eventual loss of license to practice or operate the 
equipment. As such, QA program must incorporate 
compliance with the regulatory guidelines. 
Medical centers may seek accreditation from the 
JCAHO to enhance its quality plan. Although JCAHO 
accreditation is voluntary, hospitals that do not receive 
accreditation risk losing medicare reimbursements. 
JCAHO emphasises the need to support continuous 
quality improvements (CQI). In addition, JCAHO 
requires every radiation oncology facility or department 
to maintain an updated policies and procedure manual. 
At a minimum, the policy and procedure manual should 
contain concise description of clinical procedures for 
patient evaluation, treatment plans, follow-up and 
morbidity, and mortality reviews. Procedures for 
treatment planning, treatment delivery, equipment 
quality assurance, and radiation safety should also be 
included. The manual should be updated as the procedure 
change and be reviewed at least once a year. The JCAHO 
also requires that the radiation oncology program be a 
part of hospital’s QA program. 
ESTABLISHMENT OF STANDARDS 
As stated in AAPM Report No. 13, QA in radiation 
therapy includes those procedures that ensure a 
consistent and safe fulfillment of the dose prescription to 
the target volume with minimal dose to the normal 
tissues and minimal exposure to personnel. A course of 
radiation therapy with planning and dose delivery 
exhibits a continuous process with many feedback loops 
as explained in ICRU Report No. 24. A system approach 
to radiation therapy is therefore necessary and QA at the 
each step is crucial to ensure a proper assessment of the 
results of the treatment. AAPM Report No. 13 identified 
radiation therapy as having a clinical component and a 
physical component. The report only addressed the 
physical tests and procedures necessary to ensure that a 
radiation therapy facility can accurately and reproducibly 
deliver the prescribed dose to the target volume with 
minimal dose to normal tissue. As declared, the report 
only addressed the uncertainties associated with dose 
delivery which will be discussed below. 
  The AAPM Report No. 13 stated that a QA 
document needs to have clinically relevant 
recommendations on acceptable uncertainties in 
dosimetric procedures and mechanical alignment of the 
treatment equipment. A large number of parameters, 
each with its own inaccuracy contributes to the overall 
uncertainty in the dose delivery yielding a three-
dimensional dose distribution to a patient. The 
uncertainty is determined by separating into random and 
non-random uncertainties. Random uncertainty is 
determined using statistical method and be represented 
by standard deviation. All other uncertainties (non-
random uncertainties) are to be estimated in some 
manner generally as a simple “guesstimate” roughly at 
one standard deviation of the normal distribution. The 
non-random uncertainties are combined in quadrature 
with the random uncertainties to yield a combined 
uncertainty. The combined uncertainty is multiplied by 
some factor, 2 or 3 to yield the overall uncertainty that is 
viewed upon as very approximately to the 95% or 99% 
confidence interval respectively. This methodology of 
treating QA allows some flexibility in assigning 
tolerance values to the individual components of the 
system. However, the AAPM Report No. 13 alerted that 
one to realize that (a) the overall impact of all sources of 
uncertainties must be assessed rather than concentrating 
on individual component, (b) if the geometric 
uncertainties predominate, the impact can be different in 
different areas of the patient, (c) it is necessary to assess 
the anatomic impact on the treatment uncertainties, and 
(d) the uncertainties in dose may be non-linearly in 
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relation to the geometric uncertainties and may be 
asymmetric. With this formalism, tolerance values had 
been assigned to certain tasks as listed in the AAPM 
Report No. 13. 
QA OF CLINICAL ASPECTS 
 The TG-40 report had also expanded QA program 
addressing the clinical aspects of patient care but 
excluded the medical aspects such as the decision to treat 
or the prescription of dose. The emphases of the report 
are on (a) new patient planning conference, (b) chart 
reviewing process, (c) chart checking protocol, and (d) 
film reviewing. The new patient planning conference 
stresses “the need to know” so that the radiation 
oncology team can be prepared before the patient arrives 
at the facility to initiate radiation therapy. During the 
conference pertinent information about the patient that 
needs to be presented includes (a) medical history, (b) 
physical and diagnosis assessment, (c) tumor staging, 
and (d) treatment strategy. This medical information 
allows the radiation oncology team to coordinate and 
schedule the patient in a seamless fashion especially in 
those cases where the radiation treatment is in 
combination with chemotherapy or surgery. The 
condition of the patient at the time of presentation will 
allow an assessment of whether the patient needs special 
care in the preparation of immobilisation, whether the 
patient can undergo treatment, or anticipated changes 
during treatment. The involvement of medical physics 
staff is critical at the time of presentation to ensure that 
the dose plan is designed for the individual patient in 
accordance to the treatment strategy. Technical issues 
should be discussed by all participants at the conference 
to provide appropriate patient positioning and 
immobilisation to accommodate the patient and delivers 
the prescribed dose effectively. This include the 
avoidance in the use of radiation beams that pass through 
metallic bars of the treatment couch of the machine, the 
collision of machine components, incomplete coverage 
of the target due to field size limitation, and/or abutting 
fields. Also of particular interest to the medical physics 
staff is the need to know which critical structures should 
be considered for dose computation at the time of dose 
planning, then recorded, and thereafter monitored during 
radiation treatment. 
It has been a standard practice to review verification 
film or portal weekly. However, reviewing portal in a 
conference attended by the entire treatment team would 
provide a mechanism of identifying inconsistencies if 
any between the actual and intended treatment portals by 
different observers. Once the inconsistency is detected, 
the cause can be identified and the appropriate action can 
be discussed and directly communicated. Correction 
action should be written as directives by the radiation 
oncologist so that the changes can be implemented as 
directed. Dose plan and treatment regimen should be 
discussed to communicate the current approach in regard 
to the treatment philosophy, i.e., the beam orientation, 
the number of beams used, or the patient setup. The 
number of repeated films or portals taken prior to the 
final portal should be recorded and discussed. The 
awareness of repeated portals generally indicates 
difficulty in treatment setup or degradation of the 
equipment which needs to be investigated and rectified. 
 CURRENT STATE OF QA 
The introduction of three dimensional (3D) 
treatment planning systems and innovations in 
accelerator technology in particular, the introduction of 
MLC collimation system has transformed the practice of 
radiation oncology. Patient data is no longer collected 
manually but extracted from images in particular from 
CT image dataset. Because of the large amount of digital 
data, patient data are downloaded into the treatment 
planning system through the electronic data transfer 
network. In cases where the tumors are not visible on CT 
image dataset, multi-modality imaging may be used. The 
3D treatment planning systems allow for image fusion 
and also virtual patient dose planning. After the dose 
planning, patient machine parameters are downloaded 
into the database and thereafter retrieved at the machine 
console also through the electronic data transfer network 
for dose delivery. 
Conformal radiation therapy (CRT) and IMRT 
treatment techniques are now routinely implemented in 
the clinics. The stringent requirements of CRT and 
IMRT for higher level of precision and accuracy of target 
positioning have led to the introduction of IGRT 
technology. Forced-breathing and motion-gated 
technologies have also been introduced to support CRT 
and IMRT treatment techniques. In the meantime, there 
have been advances in dose delivery technologies 
resulting in the introduction of specialised equipment 
such as the Gammaknife, Cyberknife and Helical 
Tomotherapy. Each of these therapy machines has its 
own unique equipment design and hence its own 
treatment planning software and dose delivery system 
and thereby requiring individualised QA checks. 
Because of the rapid implementation of new and 
advanced radiation oncology technologies, there have 
been wide spread concern that current QA practices and 
protocols do not provide adequately or cost-effectively 
safeguards against treatment delivery errors that have the 
potential to degrade the expected therapeutic ratio or in 
extreme cases, to cause acute injury to the patient 
undergoing radiation therapy. In September 2005, the 
National Cancer Institute (NCI) sponsored a quality 
assurance workshop to address this issue. A follow-up to 
the workshop was the symposium “Quality Assurance of 
Radiation Therapy: The Challenges of Advanced 
Technologies” held in Dallas, Texas on February 20-23, 
2007 sponsored jointly by ASTRO, AAPM, and NCI 
[12]. The first major finding of the symposium is the 
current process of developing consensus 
recommendations for prescriptive QA tests remains valid 
for many of the devices and software systems used in 
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modern radiation therapy, although for some 
technologies, QA guidance is incomplete or out of date. 
This finding is understandable with ongoing introduction 
of new radiation therapy technologies and changes in the 
principles of QA. The second major finding is the current 
approach to QA does not seem feasible for image-based 
planning, image-guided radiation therapy, and/or 
computer-controlled therapy. These modern technologies 
rely on electronic data transfer networks, electronic 
communication software, and software with 
sophisticated algorithms. The ability to test each 
individual component would seem overwhelming or 
impossible. An alternative to testing each component 
individually is to test the system as a whole. This testing 
process is often referred to as end-to-end test. End-to-end 
test has been applied in sophisticated system such as the 
robotic Cyberknife system used for focal irradiation. The 
third finding is the need for industrial engineers and 
human factor experts to make significant contributions 
towards advancing to a broader, more process-oriented 
risk-based formulation of radiation therapy QA. 
Although it sounds logical to have experts in logical 
systems and risk-based experts to assess the QA in 
radiation oncology, it is not clear how the 
recommendations can be implemented. The commitment 
of resources in terms of manpower or time allocation of 
machine for QA has been limited. In additional, medical 
physicists are more involved in the day-to-day clinics 
then ever taking away time from performing QA. The 
ability to have more manpower is very dependent on the 
economics of health care. 
TASK GROUP 100 OF AAPM 
The Task Group 100 of AAPM is currently 
developing a framework in designing quality 
management (QM) activities that would lead to the 
allocation of resources based on estimates of clinical 
outcome, risk assessment, and failure modes [14]. In this 
framework, a process tree is developed to understand the 
temporal and physical relationships between the steps 
involved in the process or procedure, for example an 
IMRT procedure. The main stream of the process is 
represented as running along the trunk of the process tree. 
The tree stems feeding into the tree trunk represent the 
major processes that are required to execute a successful 
completion of a process. An analysis methodology 
referenced to as Failure Mode and Effects Analysis 
(FMEA) focus on the process and at each step one 
considers what could possibly goes wrong, how could 
that happen, and what effects would such a failure 
produce. There can be several potential failure modes at 
each step and each failure mode can have several 
potential causes and outcomes. For example in the IMRT 
procedure, the potential failure modes can be incorrect 
patient, corrupted files, or incompatible data in the 
DICOM data transfer step. The potential causes of the 
failure are several which could be any, from inadequate 
training to incompatible DICOM format. The potential 
effects of the failure could result in the planning on the 
wrong patient or creating inappropriate dose distribution. 
For each potential cause of failure, values are assigned in 
three categories:  
●  O – the probability that a specific cause will 
result in a failure mode 
●  S – the severity of the effects resulting from a 
specific failure mode should it go undetected 
throughout the treatment 
●  D – the probability that the failure mode 
resulting from the specific cause will go 
undetected 
Conventional values of 1 to 10 are assigned to each 
category. The product of the three indices yielded the 
risk probability number (RPN=O*S*D). Decisions are 
made based on the RPN values. The RPN value of less 
than 125 is considered unimportant or of little concern. 
CURRENT TREND IN THE INDUSTRY 
Today, medical physicists in radiation oncology are 
more involved in the clinics than ever. This is due in part 
to (1) the increase use of sophisticated equipment in dose 
planning and dose delivery and (2) the implementation of 
clinical procedures requiring expertise from the medical 
physicists such as prostate implants and patient specific 
IMRT QA. Because of the transition to image-based 
technology, medical physicist have also been asked to 
solve and management networks. Medical physicist are 
also mandated by regulatory guidelines to be involved in 
clinical procedures such as treatments using remote 
afterloading high-dose rate (HDR) brachytherapy 
systems and the Gamma knife systems. It will be a 
challenge for medical physicists to allocate additional 
time for QA with these increased workloads. 
With the limited manpower, it is not unusual to have 
the commissioning of newly purchased medical linear 
accelerator outsources to an independent vendor. Some 
medical linear accelerator vendors are also providing 
experts in commissioning as part of the purchasing 
package. Medical linear accelerator vendors are now 
providing the option of having the radiation beam fine 
tuned to match standard specification of beam referred to 
as gold beam data. Based on these observations, vendors 
are aggressively making the posture of providing “ready-
to-treat” systems. In the case of interstitial brachytherapy 
procedures, third party vendors are now available to 
assay the radioactive seeds, loaded the seeds into needles, 
and then sterilised them. This third party contract has 
assisted the medical physicists in performing the clinical 
procedures of interstitial implants. Based on these trends, 
it is clear that the radiation oncology community has 
accepted the fact that medical physicists at the clinics are 
overwhelmed. 
The priority for QA in a radiation oncology facility 
is expected to be lower. Expecting additional manpower 
for QA may become more difficult in the future. The 
expectation of individual institution to perform FMEA 
for each treatment modality as expected from AAPM 
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TG-100 may be unrealistic. The only logical expectation 
is for AAPM to provide detailed FMEA but the 
assignment of values for O, S, and D are somewhat 
subjective which may not be applicable to all radiation 
oncology facilities. If the observed trend is as predicted, 
medical physicists may have time to perform 
functionality tests only. The evaluation will be based on 
the end-to-end test methodology. Any assessment will be 
based on baseline performance and the analysis will be 
based on a pass/fail test formalism set forth by the 
vendors. The challenge for future medical physicists will 
be to identify those critical tasks that must be performed 
and the appropriate frequency of checks in order to 
maximize patient care with limited manpower in the 
individual clinics. 
SUMMARY 
The technical aspects of QA program in radiation 
oncology as practice in the US is described in the spirit 
of sharing with the radiation oncology communities in 
the Asia-Pacific region. A comprehensive QA program 
will have an official statement declaring the quality plan 
for effective patient care services it provides in a 
document. The document will also describe the 
organisational structure, responsibilities, checks and 
procedures, and resources allocated to ensure the 
successful implementation of the quality of patient 
management. Regulatory guidelines and guidelines from 
accreditation agencies must be included in the QA 
program to ensure compliance. The organisational 
structure will have a multidisciplinary QA committee 
that evaluates the effectiveness of the QA program 
continuously to provide prompt correctively measures 
and to request feedback as needed. To ensure that a QA 
program is effective, the program itself needs to be 
audited for quality at regular intervals. 
The current QA program has been recognised to be 
inadequate in keeping pace with the rapid advancement 
of radiation therapy technologies in particular with the 
introduction of the image-based technologies. This 
inadequacy is of concern to the federal agency and 
societal bodies that led to having workshops to address 
this issue with the most recent being held in Dallas, 
Texas in 2007. At the present time, industrial engineers 
are being recruited to assist in devising a methodology 
that is broad-based and more process-oriented risk-based 
formulation of QA in radiation oncology. 
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